


PZ-II-029

Cat. No.:	HY-120837
CAS No.:	164025-44-9
Molecular Formula:	C ₁₈ H ₁₅ N ₃ O ₃
Molecular Weight:	321.33
Target:	GABA Receptor
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to $\alpha 6\beta 3\gamma 2$. PZ-II-029 shows anti-migraine effects ^[1] .	
In Vivo	PZ-II-029 (1-10 mg/kg; i.p.; 30 min before Capsaicin instillation) inhibits central and peripheral trigeminal responses in a rat migraine model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Wistar rats (250-300 g; 8-10 weeks) induced by intra-cisternal (i.c.) instillation of Capsaicin ^[1] .
	Dosage:	1, 3, or 10 mg/kg
	Administration:	i.p.; 30 min before Capsaicin instillation
	Result:	Significantly attenuated the trigeminal cervical complex (TCC) neuronal activation and trigeminal ganglia (TG) calcitonin gene-related peptide immunoreactivity (CGRP-ir) elevation, and dural CGRP depletion induced by capsaicin.

REFERENCES

[1]. Pi-Chuan Fan, et al. The $\alpha 6$ subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation. *Neuropharmacology*. 2018 Sep 15;140:1-13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA